Sascha A Tuchman
Alliance for Clinical Trials in Oncology
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Sascha A Tuchman as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:42 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06179888 · Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple MyelomaNational Cancer Institute (NCI) · suspended · Multiple Myeloma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 12:42 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Alliance for Clinical Trials in Oncology Member Site CoreU10CA180821 · NCI · ALLIANCE NCTN FOUNDATION · PI Evanthia Galanis · fiscal years 2014 to 2026Named on NCT06179888
Most cited trial papers
Clinical-trial papers with this author name in multiple myeloma, ranked by citations from NIH iCite, fetched 2026-11-12 12:42 UTC. The ranking covers the 200 most relevant of 8 PubMed records, and a shared surname and initials can bring in a namesake. All 8 on PubMed
- Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients.Br J Cancer · 202240 citationsRCR 2.7
- 39 citationsRCR 1.9
- A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202).Am J Hematol · 202124 citationsRCR 1.1
- Phase I study of opaganib, an oral sphingosine kinase 2-specific inhibitor, in relapsed and/or refractory multiple myeloma.Ann Hematol · 202322 citationsRCR 2.2
- 20 citationsRCR 1.0
- A phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma.Blood Cancer J · 202116 citationsRCR 0.8
- Phase 1 open-label study of panobinostat, lenalidomide, bortezomib + dexamethasone in relapsed and relapsed/refractory multiple myeloma.Blood Cancer J · 202111 citationsRCR 0.6
- Phase II study of dose-attenuated bortezomib, cyclophosphamide and dexamethasone ("VCD-Lite") in very old or otherwise toxicity-vulnerable adults with newly diagnosed multiple myeloma.J Geriatr Oncol · 201710 citationsRCR 0.4